An in vitro experimental pipeline to characterize the binding specificity of SARS-CoV-2 neutralizing antibodies
Description
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 760 million cases and >6.8 million deaths worldwide. We developed a panel of human neutralizing monoclonal
